Neurodegenerative Disorders Articles & Analysis
63 news found
Researchers have long recognized the importance of CCM in regulating cellular function and contributing to the understanding of various diseases, including cancer, diabetes, and neurodegenerative disorders. However, traditional methods of analyzing these complex metabolic networks have often fallen short, hindering progress in the field. ...
This new panel enables rapid and accurate detection of mutations in mitochondrial DNA (mtDNA) that are associated with a wide range of mitochondrial disorders. Mitochondrial diseases are a complex and heterogeneous group of disorders caused by mutations in mitochondrial DNA (mtDNA) or nuclear genes that encode proteins involved in mitochondrial function. The ...
Today, scientists are amassing a new arsenal of magic bullets, and new companies are proliferating to carry them forward in the war against cancer and a host of other diseases and disorders. Advances in cell replacement therapy, for example, are making it possible for scientists to genetically engineer a patient’s own T-cells so they can specifically target antigens ...
Anle138b was initially developed in patients with MSA and PD and has the potential to be applied to other neurodegenerative disorders, such as Alzheimer's disease. A Phase 1b (NCT04685265) clinical trial evaluating the safety of the compound, as well as efficacy measures in patients living with PD, is currently being conducted. ...
Bioactive lipids are consistently involved in chronic inflammation for pathological characterization, such as cancer, diabetes, atherosclerosis, asthma, inflammatory bowel disease, as well as autoimmune and neurodegenerative disorders. “With years of experience in lipid chemistry, Alfa Chemistry now provides a full range of fatty acids and esters, ...
“There is a significant need in the field of neurodegenerative diseases for novel treatment strategies, specifically solutions that are cost-effective and globally scalable,” said Bill Erhardt, M.D., Chief Medical Officer of Oligomerix. ...
Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, today announced that the U.S. ...
Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for Alzheimer’s and rare neurodegenerative diseases, announced that the Company presented data from a therapeutic study in an animal model of its lead product candidate OLX-07010 at the 14th Annual Clinical Trials on Alzheimer's Disease (CTAD) conference and at ...
Its most advanced program BRT-DA01 is being developed for the treatment of Parkinson’s disease, a progressive neurodegenerative disorder caused by nerve cell damage in the brain. It comprises of pluripotent stem cell-derived dopaminergic neurons that are implanted into the brain, thus taking target at the root cause of the disease. ...
ByBayer AG
“With millions of Americans suffering from Alzheimer’s disease and other neurodegenerative disorders, patients are desperate for safer, accessible and more effective treatment options,” said James Moe, Ph.D., MBA, CEO and Head of Discovery and Strategy at Oligomerix. ...
The library of compounds can be selected to target (personalize) the treatment of neuropsychiatric, and neurodegenerative, neuroinflammatory and pain disorders including depression, as well as tobacco, opiate (OUD), and cocaine addiction, alcoholism (AUD), post-traumatic stress disorder (PTSD), and pain syndromes including cluster headaches and ...
Ariana Pharma, the leading Al-driven precision medicine company, has announced the first comprehensive blarcamesine pathway analysis impact using extensive data from the ANAVEX®2-73-PDD-001 Parkinson’s Disease Dementia (PDD) clinical study. Initial results were presented by Ariana Pharma at the Alzheimer’s Association International Conference (AAIC 2022) in San Diego, in ...
Through the support of our two recent NIH awards and our world-class investor consortium, we are excited by the potential to bring a novel therapeutic option to the millions of patients with AD and other neurodegenerative diseases.” Oligomerix has completed the preclinical work needed to support an investigational new drug (IND) application with the U.S. ...
“Krabbe disease is a rapidly fatal neurodegenerative disorder. While early transplant can help patients, they inevitably develop motor disease. ...
Kurve Therapeutics is ready for Phase III clinical trials in three separate disease states and is positioned to make a critical impact on the neurodegenerative disease treatment market. Kurve Therapeutics has developed a cutting-edge approach to treating central nervous system (CNS) disorders. These debilitating disorders afflict millions of ...
Beacon Biosignals, a startup that applies AI to EEG to unlock precision medicine for neurological and psychiatric disorders, presented research at the Alzheimer's Association International Conference, which took place July 31–Aug. 4, 2022, in San Diego. ...
Kurve Therapeutics has succeeded in bypassing the blood-brain barrier with their patented Controlled Particle Dispersion® (CPD) technology, creating new hope in the treatment of central nervous system disorders. The company urges CNS researchers to reach out for collaboration in providing care for this very large global population. ...
About Alzheimer’s Disease Alzheimer’s disease (AD), the most common form of dementia, is a progressive neurodegenerative disorder that slowly destroys memory and cognitive skills and eventually the ability to carry out simple tasks. ...
ByVaxxinit
Research reported in this publication was supported by the National Institute Of Neurological Disorders And Stroke (NINDS) of the National Institutes of Health (NIH) under Award Number R42NS120548. ...
EEG is standard of care in the clinical diagnosis and management of many neurologic diseases and sleep disorders, yet features of clinical significance often are difficult to extract from EEG data. ...